Sir, Pyogenic granulomas are benign, reactive, typically superficial vascular lesions that can be idiopathic or arise secondary to trauma, underlying vascular malformations, infections, physiologic or pathologic endocrine changes, and hormone therapy. 1 Rarely, subcutaneous and intravascular lesions have been described in literature. Most cases occur as solitary lesions; but multiple, grouped and disseminated lesions have been described. 2 Papular lesions in a linear distribution have never been reported. The diagnosis of pyogenic granuloma is confirmed by histology.
A 57-year-old male presented with multiple asymptomatic nodules over the left-side forehead and eyebrow since the past 5 years. These lesions were increasing in number with appearance of new nodules at 2-3 months interval. He was diagnosed to have hepatocellular carcinoma 10 years back, which had completely resolved after chemotherapy. On clinical examination, there were multiple skin-colored to slightly erythematous soft nontender sessile, mobile growths in groups with a linear distribution over the left-side forehead, left eyebrow, and left upper eyelid [ Figure 1 ]. There was no preceding history of prolonged drug intake or trauma prior to the appearance of the lesions or any history of bleeding from the site. There was no other significant cutaneous or systemic findings. Based on the history and clinical examination, benign vascular tumor and metastatic hepatocellular carcinoma were considered as differential diagnosis. The dermoscopic examination showed white areas in the center with surrounding rim of red circles and telangiectasias, suggestive of a vascular tumor. Hence, a clinical possibility of vascular tumor was considered. Routine investigations such as complete hemogram, liver, and renal function tests were within normal limits. Doppler ultrasonographic examination showed no intra-orbital or intracranial extensions. On histopathological examination, there were lobules of proliferating capillaries lined by single layer of endothelial cells separated by fibrous strands in the mid dermis level without any change in the epidermis [Figures 2 and 3 ]. Thus, a final diagnosis of pyogenic granuloma was made. The patient was treated with excision and cauterisation of the lesion. He was followed up for 6 months with no recurrence.
Lobular capillary hemangioma or pyogenic granuloma is a common benign vascular proliferation. Typically, these lesions occur in the superficial dermis; although rare, subcutaneous and intravascular lesions can occur. 3 Clinically, the lesions are described as painless skin-colored to erythematous papules and nodules, with few of them showing surface erosion. Our patient had multiple soft nontender skin-colored to erythematous papules and nodular growths present in grouped pattern over the left side of the forehead, left eyebrow, and upper eyelid, but the linear distribution of the lesions in our case is unusual.
Dermoscopy of pyogenic granuloma shows homogeneous reddish or white-red areas(proliferating capillaries and veins) surrounded by whitish collarette(surrounding epidermal collarette in histopathology). An atypical dermoscopic pattern characterized by the presence of a central, irregular, whitish-yellow amorphous structure with a peripheral crown of polymorphous, atypical vessels has also been reported. Our case had central white areas and rim of reddish areas. Diagnosis is by histopathologic examination which shows immature capillaries with interspersed fibroblastic tissue, 
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resembling granulation tissue in an edematous matrix. The deeper portion of the lesion has proliferating capillaries arranged in a lobular pattern extending into the deep dermis, with a dense, fibrous stroma. 4 Our patient had thin-walled capillaries in the deeper dermis with intervening fibrous stroma. Pyogenic granuloma has to be differentiated from tufted angioma histopathologically. In case of tufted angioma, the endothelial cells are plump and the lumen is usually obliterated, with lobules composed of bloodless capillaries surrounded by dilated crescent-shaped vascular channels. The angiomatous tissue in pyogenic granuloma is composed of dilated network of blood-filled capillaries and groups of poorly canalized vascular tufts surrounded by myxoid stroma.
Numerous treatment methods have been described for pyogenic granuloma: curettage, shave excision, laser therapy, or excision. Because the lesion can involve the reticular dermis, it may be out of the reach of the pulsed-dye laser, cautery, or shave excision. Definitive management requires full-thickness skin excision. 5 Localized recurrence after excision and satellite spread of the lesions is known. Our patient opted for surgical excision for cosmetic purpose, and there was no recurrence after the procedure.
Our patient had asymptomatic soft grouped papulonodules with linear distribution. Dermoscopy showed vascular nature of the lesion. Histopathology proved the diagnosis to be pyogenic granuloma. We report this case for its unique linear pattern of distribution.
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Multiple cherry angiomas and pyogenic granuloma in a patient treated with ramucirumab and paclitaxel
Sir, Secondary neoplasm may develop as a side effect of chemotherapy. 1-3 Anticancer drugs reported to cause secondary neoplasm are mainly the classic chemotherapeutic agents, including alkylating agents, possibly caused by the effects of DNA damage and immunosuppression. 2 Recently, there have been reports that newer anticancer drugs, including targeted agents and checkpoint inhibitors, may induce secondary neoplasm, such as vemurafenib-induced squamous cell carcinoma and keratoacanthoma. 3 Ramucirumab, one of the newer anticancer drugs, is a fully-human monoclonal antibody targeting the extracellular domain of vascular endothelial growth factor receptor-2 (VEGFR-2) thereby blocking proangiogenic effects of vascular endothelial growth factor (VEGF). 1, [4] [5] [6] The drug is used for treatment of gastric, colorectal and non-small cell lung cancers. 1, 5, 6 We present a case of two different vascular lesions, cherry angioma and pyogenic granuloma, which occurred after treatment with the newer anticancer drug ramucirumab and classic chemotherapeutic agent paclitaxel.
A 40-year-old man presented with 8 mm sized, reddish, dome-shaped, bleeding nodule on the left parietal region of the scalp [ Figure 1a ]. He also reported newly appeared multiple tiny erythematous papules on the face and the neck [ Figure 1a and b]. He had history of advanced gastric cancer with metastasis to the omentum, pelvic cavity, and transverse mesocolon treated with capecitabine combined with oxaliplatin. Four months later, due to progression of advanced gastric cancer, capecitabine and oxaliplatin were discontinued. Subsequently, the patient was treated with ramucirumab (8 mg/kg) every two weeks and paclitaxel (80 mg/m 2 ) once a week. Four months after starting the changed regimen, he came to our clinic due to the development of lesions described above. for which he claimed no preceding trauma. We performed excisional biopsy on the scalp lesion. The histopathological findings showed dilated capillary vessel proliferation and lymphohistiocytic infiltration in the dermis with epidermal collarettes [ Figure 2 ]. The scalp mass was diagnosed as pyogenic granuloma, and multiple reddish papules on the face and the neck were clinically diagnosed as cherry angioma. He opted to treat the multiple cherry angiomas for cosmetic reasons and they were removed with carbon dioxide laser. Ramucirumab and paclitaxel was also discontinued due to progression of advanced gastric cancer. The patient was started on pembrolizumab after stopping ramucirumab. Four months after discontinuation of ramucirumab, there were no new lesions.
Angiogenesis is one of the hallmarks of cancer and therapies targeting angiogenesis are integral modalities in cancer treatment. 1, 7 As there is increased expression and secretion of the key angiogenesis regulators VEGF and VEGFR in cancers, several newer anticancer drugs inhibiting this pathway have been developed, one of them is ramucirumab. 1, 7 In the English literature, we found only eight cases which reported vascular lesions following treatment with ramucirumab [ Table 1 ]. 1, 4, 5, 8 Seven of the nine cases reported ramucirumab treatment combined with taxanes. 4, 5, 8 In six of these seven cases,
